{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:05:48Z","timestamp":1781006748307,"version":"3.54.1"},"reference-count":31,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501600"],"award-info":[{"award-number":["2023ZD0501600"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,19]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second-line systemic therapy (SLST). This trial aims to evaluate whether continuing FLST combined with radiotherapy (RT) to oligoprogressive lesions can improve progression-free survival (PFS) compared with an early switch to SLST in patients with oligoprogressive HCC while maintaining an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma trial is a prospective, multicentre, randomised phase III study that will enrol 132 patients with advanced HCC who experience their first oligoprogression during FLST. Oligoprogression is defined as one to five\u2009progressive lesions involving no more than one to three organs. Participants will be randomised (1:1) to either continuation of FLST combined with RT to all oligoprogressive lesions or discontinuation of FLST followed by initiation of SLST. RT will be delivered with a biologically effective dose (linear\u2013quadratic model, \u03b1\/\u03b2=10) of at least 60\u2009Gy whenever feasible. The primary endpoint is PFS. Secondary endpoints include overall survival, objective response rate, disease control rate, duration of response and quality of life. Predefined exploratory analyses include circulating tumour DNA profiling, optional paired tumour biopsies, functional imaging with fibroblast activation protein inhibitor positron emission tomography-CT and longitudinal immune profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      This study has been approved by the Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University (number: SDZLEC2025-025-02) and has been registered in ClinicalTrials. gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06841172\">NCT06841172<\/jats:ext-link>\n                      ). Final study results will be disseminated through peer-reviewed journals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06841172\">NCT06841172<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118739","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:50:31Z","timestamp":1781005831000},"page":"e118739","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06841172","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06841172","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06261047","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06841172","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06841172","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Haohua","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"},{"name":"Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-6554","authenticated-orcid":false,"given":"Jinbo","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong First Medical University Cancer Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026060904501525000_16.6.e118739.1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394"},{"key":"2026060904501525000_16.6.e118739.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2"},{"key":"2026060904501525000_16.6.e118739.3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026060904501525000_16.6.e118739.4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"The Lancet"},{"key":"2026060904501525000_16.6.e118739.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002"},{"key":"2026060904501525000_16.6.e118739.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"2026060904501525000_16.6.e118739.7","doi-asserted-by":"crossref","first-page":"104522","DOI":"10.1016\/j.critrevonc.2024.104522","article-title":"Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials","volume":"204","author":"Wang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026060904501525000_16.6.e118739.8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"key":"2026060904501525000_16.6.e118739.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"2026060904501525000_16.6.e118739.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026060904501525000_16.6.e118739.11","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.3390\/curroncol30100633","article-title":"The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence","volume":"30","author":"Cerreto","year":"2023","journal-title":"Curr Oncol"},{"key":"2026060904501525000_16.6.e118739.12","doi-asserted-by":"crossref","first-page":"110505","DOI":"10.1016\/j.radonc.2024.110505","article-title":"Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis","volume":"200","author":"Tan","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026060904501525000_16.6.e118739.13","doi-asserted-by":"crossref","first-page":"110288","DOI":"10.1016\/j.radonc.2024.110288","article-title":"Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer","volume":"196","author":"Doyle","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026060904501525000_16.6.e118739.14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2024.03.003","article-title":"Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study","volume":"81","author":"Choi","year":"2024","journal-title":"J Hepatol"},{"key":"2026060904501525000_16.6.e118739.15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2024.12.039","article-title":"Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma","volume":"122","author":"Leng","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060904501525000_16.6.e118739.16","doi-asserted-by":"crossref","unstructured":"Shi F , Wang H , Yang Y , et al . Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial. Clin Cancer Res 2026;OF1\u20137. doi:10.1158\/1078-0432.CCR-25-4502","DOI":"10.1158\/1078-0432.CCR-25-4502"},{"key":"2026060904501525000_16.6.e118739.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2026060904501525000_16.6.e118739.18","doi-asserted-by":"crossref","unstructured":"Wang H , Zhang X , Zhu K , et al . Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial. Ther Adv Med Oncol 2025;17. doi:10.1177\/17588359251334538","DOI":"10.1177\/17588359251334538"},{"key":"2026060904501525000_16.6.e118739.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07033-7","article-title":"Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal\/pelvic lymph nodes: a retrospective study","volume":"20","author":"Ito","year":"2020","journal-title":"BMC Cancer"},{"key":"2026060904501525000_16.6.e118739.20","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1093\/oncolo\/oyad083","article-title":"Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"2026060904501525000_16.6.e118739.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1754"},{"key":"2026060904501525000_16.6.e118739.22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000537966","article-title":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"2026060904501525000_16.6.e118739.23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ijrobp.2022.08.027","article-title":"Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials","volume":"114","author":"Kim","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060904501525000_16.6.e118739.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30537-4"},{"key":"2026060904501525000_16.6.e118739.25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.21037\/tlcr.2018.09.21","article-title":"Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease","volume":"8","author":"Ning","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2026060904501525000_16.6.e118739.26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4143\/crt.2022.329","article-title":"Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis","volume":"54","author":"Rim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"2026060904501525000_16.6.e118739.27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2026060904501525000_16.6.e118739.28","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026060904501525000_16.6.e118739.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026060904501525000_16.6.e118739.30","doi-asserted-by":"crossref","first-page":"110889","DOI":"10.1016\/j.radonc.2025.110889","article-title":"A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment","volume":"207","author":"Gkika","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026060904501525000_16.6.e118739.31","unstructured":"Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial[J]. Clin Cancer Res 2026."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:50:39Z","timestamp":1781005839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2026-118739"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118739","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}